UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000026475
Receipt number R000029143
Scientific Title A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Date of disclosure of the study information 2017/03/09
Last modified on 2024/04/05 19:41:26

No. Disposal Last modified on Item of update
1 Insert 2017/03/09 16:06:52
2 Update 2017/06/30 15:38:40 Organization
Organization
3 Update 2017/08/21 15:41:03 Organization1
Institutions
4 Update 2017/08/21 15:42:09 Anticipated trial start date
5 Update 2017/09/20 18:39:29 Recruitment status
6 Update 2018/03/13 11:25:38 Institutions
7 Update 2018/03/13 11:47:30 Interventions/Control_1
Interventions/Control_1
Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
Target sample size
8 Update 2018/09/13 14:42:48 Name of person sending information
Name of person sending information
9 Update 2018/09/13 14:49:16 Recruitment status
10 Update 2019/07/01 15:09:11 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
11 Update 2019/07/01 15:11:26 Number of participants that the trial has enrolled
12 Update 2019/07/01 15:19:33 Date of IRB
Last follow-up date
13 Update 2022/09/22 10:47:17 Email
Organization
Organization
Email
14 Update 2022/09/22 10:50:51 URL releasing protocol
URL related to results and publications
Results
Results
Results date posted
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
15 Update 2024/02/15 15:10:48 UMIN ID1
16 Update 2024/04/05 19:41:26 UMIN ID2